Conformational Restriction and/or Steric Hindrance in Medicinal Chemistry

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 363-379

  Mann, André ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882530434     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00017-2     Document Type: Chapter

References (50)

1. Jencks W. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. USA 1981, 78:4046-4050.
2. Raffa R.B., Porreca F. Thermodynamic analysis of the drug-receptor interaction. Life Sci. 1989, 44:245-258.
3. Andrews P.R., Craik D.J., Martin J.L. Functional group contributions to drug-receptor interactions. J. Med. Chem. 1984, 27:1657-1684.
4. Page M.I. Entropie, Bindungsenergie und enzymatische Katalyse. Angew. Chem. 1977, 89:456-467.
5. Bardi S.J., Luque I., Freire E. Structure-based thermodynamic analysis of HIV-1 protease inhibitors. Biochemistry 1997, 36:6588-6596.
6. Velazquez-Campoy A., Todd M.J., Freire E. HIV-1 Protease inhibitors: enthalpic versus entropic optimization of the binding affinity. Biochemistry 2000, 39:2201-2207.
7. Searle M.S., Williams D.H. The cost of conformational order: entropy changes in molecular associations. J. Am. Chem. Soc. 1992, 114:10690-10697.
8. Williams D.H., Westwell M.S. Aspects of weak interactions. Chem. Soc. Rev. 1998, 27:57-63.
9. Williams D.H., Stephens E., O'Brien D.P., Zhou M. Understanding noncovalent interactions: ligand binding energy and catalytic efficiency from ligand-induced reductions in motion within receptors and enzymes. Angew. Chem. Int. Ed. 2004, 43:6596-6616.
10. Davis A.M., Teague S.J. Hydrogen bonding hydrophobic interactions, and failure of the rigid receptor hypothesis. Angew. Chem. Int. Ed. 1999, 38:736-749.
11. Böhm H.J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput.-Aided Mol. Des. 1994, 8:243-256.
12. Gilli P., Ferretti V., Gilli G. Enthalpy-entropy compensation in drug-receptor binding. J. Phys. Chem. 1994, 98:1515-1518.
13. Velazquez-Campoy A., Luque I., Freire E. The application of themodynamic methods in drug design. Thermochim. Acta 2001, 380:217-227.
14. Weiland G.A., Minnemann K.P., Molinoff P.B. Fundamental difference between the molecular interactions of agonists and antagonists with the β-adrenergic receptor. Nature 1979, 281:114-117.
15. Miklavc A., Kocjan D., Mavri J., Koller J., Hadzi D. On the fundamental difference in the thermodynamics of agonist and antagonist interactions with β-adrenergic receptors and the mechanism of entropy driven binding. Biochem. Pharmacol. 1990, 40:663-669.
16. Borea P.A., Dalpiaz K., Varani K., Guerra G., Gilli G. Binding thermodynamics of adenosine A2a receptor ligands. Biochem. Pharmacol 1995, 49:461-472.
17. Gilli P., Gilli G., Borea P.A., Varani K., Scatturin A., Dalpiaz A. Binding thermodynamics as a tool to investigate the mechanisms of drug-receptor interactions: thermodynamics of cytoplasmic steroid/ nuclear receptors in comparison with membrane receptors. J. Med. Chem 2005, 48:2026-2035. and references therein.
18. Hruby V.J., Li G., Hacksell-Luevano C., Shenderovich M. Design of peptides, proteins and peptidomimetics in chi space. Biopolymers 1997, 43:219-266. and references cited therein.
19. Leach A.R., Lewis R.A. A racing-bracing approach to computer-assisted ligand design. J. Comp. Chem. 1994, 15:233-240.
20. Nicklaus M.C., Wang S., Driscoll J.S., Milne G.W.A. Conformational changes of small molecules binding to proteins. Bioorg. Med. Chem. 1995, 3:411-428.
21. Charton M., Motoc I. Steric effects in drug design. Top. Curr. Chem. 1983, 114:1-6.
22. Veber D.F., Johnson S.R., Cheng H.-Y., Smith B.R., Ward K.W., Kopple K.D. Molecular properties the influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45:2615-2623.
23. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23:4-25.
24. Gougat J., Ferrari B., Sarran L., Planchenault C., Poncelet M., Maruani J., Alonso R., Cudennec A., Tiziano Croci T., Fabio Guagnini F., Katalin Urban-Szabo K., Martinolle J.P., Soubrié P., Finance O., Le Fur G. SSR240612 [(2R)-2-[((3R)-3-(1,3-Benzodioxol-5-yl)-3-{[(6-methoxy-2-naphthyl)sulfon yl]amino}propanoyl)amino]-3-(4-{[2R,6S)-2,6-dimethylpiperidinyl]methyl}p henyl)-N-isopropyl-N-methylpropanamide Hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 2004, 309:661-669.
25. D'Amico D.C., Aya T., Human J., Fotsch C., Chen J.J., Biswas K., Riahi B., Norman M.H., Willoughby C.A., Hungate R., Reider P.J., Biddlecome G., Lester-Zeiner D., Van Staden C., Johnson E., Kamassah A., Arik L., Wang J., Viswanadham V.N., Groneberg R.D., Zhan J., Suzuki H., Toro A., Mareska D.A., Clarke D.E., Harvey D.M., Burgess L.E., Laird E.R., Askew B., Ng G. Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity. J. Med. Chem. 2007, 50:607-610.
26. Shannon C.E. Prediction and entropy. Bell Sys. Tech. J. 1951, 16:50-64.
27. Viswanadham V.N., Mattice W.L. Assessment of bond rotation interdependence in polymer chains: an information theory approach. Macromolecules 1987, 20:685-688.
28. Calderone C.T., Williams D.H. An enthalpic component in cooperativity: the relationship between enthalpy, entropy, and noncovalent structure in weak associations. J. Am. Chem. Soc. 2001, 123:6262-6267.
29. Watanabe M., Kazuta Y., Hayashi H., Yamada S., Matsuda A., Shuto D. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure. J. Med. Chem. 2006, 49:5587-5596.
30. Ali S.M., Tedford C.E., Gregory R., Handley M.K., Yates S.L., Hirth W.W., Phillips J.G. Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists. J. Med. Chem. 1999, 42:903-909.
31. Kazuta Y., Hirano K., Natsume K., Yamada S., Kimura R., Matsumoto S.-i., Furuichi K., Matsuda A., Shuto S. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-Aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure. J. Med. Chem. 2003, 46:1980-1988.
32. Ohmori Y., Yamashita A., Tsujita R., Yamamoto T., Taniuchi K., Matsuda A., Shuto S. A method for designing conformationally restricted analogues based on allylic strain: synthesis of a novel class of noncompetitive NMDA receptor antagonists having the acrylamide structure. J. Med. Chem. 2003, 46:5326-5333.
33. Schreiber S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 2000, 287:1964-1969.
34. Burke M.D., Schreiber S.L. A planning strategy for diversity-oriented synthesis. Angew. Chem. Int. Ed. 2004, 43:46-58.
35. Daly J.W., Garraffo H.M., Spande T.F., Decker M.W., Sullivan J.P., Williams M. Alkaloids from frog skin: the discovery of epibatidine and the potential for developing novel non-opioid analgesics. Nat. Prod. Rep. 2000, 17:131-135.
36. Abe H., Arai Y., Aoyagi S., Kibayashi C. Synthesis of conformationally constrained spirodihydrofuropyridine analogues of epibatidine. Tetrahedron Lett. 2003, 44:2971-2973.
37. Brieaddy L.E., Mascarella S.W., Navarro H.A., Atkinson R.N., Damaj M.I., Martin B.R., Carroll F.Y. Synthesis of bridged analogs of epibatidine 3-Chloro-5,7,8,9,9a,10-hexahydro-7,10-methanopyrrolo[1,2-b]-2,6-naphthyr idine and 2-chloro-5,5a,6,7,8,10-hexahydro-5,8-methanopyrrolo[2,1-b]-1,7-naphthyri dine. Tetrahedron Lett. 2001, 42:3795-3797.
38. Hirashima S., Suzuki T., Ishida T., Noji S., Yata S., Ando I., Komatsu M., Ikeda S., Hashimoto H. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J. Med. Chem. 2006, 49:4721-4736.
39. Ikegashira K., Oka T., Hirashima S., Noji S., Yamanaka H., Hara Y., Adachi T., Tsuruha J.-I., Doi S., Hase Y., Noguchi T., Ando I., Ogura N., Ikeda S., Hashimoto H. Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors. J. Med. Chem. 2006, 49:6950-6953.
40. Meunier J.C., Molereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., Monsarrat B., Mazarguil H., Vassart G., Parmentier M., Costentin J. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995, 377:532-535.
41. Kawamoto H., Ozaki S., Itoh Y., Miyaji M., Arai S., Nakashima H., Kato T., Ohta H., Iwasawa Y. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl- 1,3-dihydro-2H-benzimidazol-2-one (J-113397). J. Med. Chem. 1999, 42:5061-5063.
42. Jong L., Zaveri N., Toll L. The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands. Bioorg. Med. Chem. Lett. 2004, 14:181-185.
43. Thomas J.B., Mascarella S.W., Rothman R.B., Partilla J.S., Xu H., McCullough K.B., Dersch C.M., Cantrell B.E., Zimmerman D.M., Carroll F.I. Investigation of the N-substituent conformation governing potency and receptor subtype-selectivity in (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)- piperidine opioid antagonists. J. Med. Chem. 1998, 41:1980-1990.
44. Le Bourdonnec B., Goodman A.J., Michaut M., Ye H.-F., Graczyk T.M., Belanger S., Herbertz T., Yap G.P.A., DeHaven R.N., Dolle R.E. Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of -opioid receptor antagonists. J. Med. Chem. 2006, 49:7278-7289.
45. Gao Y., Wei C.-Q., Burke T.R. Olefin metathesis in the design and synthesis of a globally constrained Grb2 SH2 domain inhibitor. Org. Lett. 2001, 3:1617-1620.
46. Furet P., Gay B., Caravatti G., Garcia-Echeverria C., Rahuel J., Schoepfer J., Fretz H. Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain. J. Med. Chem. 1998, 41:3442-3449.
47. Martin S.F. Preorganization in biological systems: Are conformational constraints worth the energy?. Pure Appl. Chem. 2007, 79:193-200.
48. Benfield A.P., Teresk M.G., Plake H.R., DeLorbe J.E., Millspaugh L.E., Martin S.F. Ligand preorganization may be accompanied by entropic penalties in protein-ligand interactions. Angew. Chem. Int. Ed. 2006, 45:6830-6835.
49. Martin S.F., Dorsey G.O., Gane T., Hillier M.C., Kessler H., Baur M., Mathae B., Erickson J.W., Bhat T.N., Munshi S., Gulnik S.V., Topol I.A. Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors. J. Med. Chem. 1998, 41:1581-1597.
50. Martin S.F., Austin R.E., Oalmann C.J., Baker W.R., Condon S.L., DeLara E., Rosenberg S.H., Spina K.P., Stein H.H., Cohen J., Kleinert H.D. 1,2,3-trisubstituted cyclopropanes as conformationally restricted peptide isosteres: application to the design and synthesis of novel renin inhibitors. J. Med. Chem. 1992, 35:1710-1721.